CoChat
Sign Up
Cited by 42

The DOI matches its Crossref record.

Effects of Cardiac Versus Circulatory Angiotensin-Converting Enzyme Inhibition on Left Ventricular Diastolic Function and Coronary Blood Flow in Hypertrophic Obstructive Cardiomyopathy

Kyriakidis, Michael, Triposkiadis, Filippos, Dernellis, John, Androulakis, Aristides E., Mellas, Panagiotis, Kelepeshis, Glafkos A., Gialafos, John E.·1998·Circulation
DOI 10.1161/01.cir.97.14.1342
Open this paper in CoChat — free account

Abstract

Background —Left ventricular (LV) diastolic function and coronary flow are impaired in hypertrophic obstructive cardiomyopathy (HOCM). This study was designed to evaluate the impact of cardiac and circulatory ACE inhibition on such derangements. Methods and Results —Twenty patients with HOCM underwent cardiac ACE inhibition with intracoronary (IC) enalaprilat (0.05 mg/min infused into the left anterior descending coronary artery for 15 minutes) followed by circulatory ACE inhibition with 25 mg sublingual (SL) captopril. Contrast ventriculography, pressure, and coronary flow measurements were performed at baseline, after IC enalaprilat infusion, and 45 minutes after SL captopril. Heart rate was not affected by the respective interventions (75±11 versus 76±13 versus 75±10 bpm; P =NS), whereas mean aortic pressure dropped slightly after IC enalaprilat and significantly after SL captopril (90±8 versus 85±10 versus 74±9 mm Hg; P <.05). Compared with baseline, IC enalaprilat resulted in a decrease in LV end-diastolic pressure (17.6±5.9 versus 14.4±4.9 mm Hg; P <.05), time constant of isovolumic LV pressure relaxation (τ G ) (69±9 versus 52±10 ms; P <.05), and outflow gradient (45.2±6.9 versus 24.4±3.7 mm Hg; P <.05) and in an increase in coronary blood flow (107±10 versus 127±12 mL/min; P <.05) and coronary flow reserve (2.2±0.4 versus 2.6±0.3; P <.05). After SL captopril, τ G was prolonged (60±13 ms; P <.05 versus IC enalaprilat), and LV outflow gradient, coronary blood flow, and coronary flow reserve values returned to baseline (45.5±5.3 mm Hg, 107±12 mL/min, and 2.2±0.5, respectively; P =NS versus baseline). Conclusions —Activation of the cardiac renin-angiotensin system contributes to LV diastolic dysfunction as well as to the decreased coronary blood flow and coronary flow reserve in HOCM. Cardiac ACE inhibition restores and circulatory ACE inhibition aggravates the above derangements.

Overview

Integrity signals

Registry

Crossref · 10.1161/01.cir.97.14.1342

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 38

  1. 10.1016/0033-0620(85)90024-6 · DOI
  2. 10.1056/NEJM198703263161305 · DOI
  3. 10.1056/NEJM198704023161405 · DOI
  4. 10.1161/circ.92.7.1680 · DOI
  5. 10.1016/0002-8703(95)90213-9 · DOI
  6. 10.1161/circ.92.7.1808 · DOI
  7. 10.1016/0140-6736(93)92061-W · DOI
  8. 10.1161/circ.89.6.8205673 · DOI
  9. 10.1161/circ.90.6.7994819 · DOI
  10. 10.1161/circ.87.3.8383016 · DOI
  11. 10.1161/circ.93.9.1734 · DOI
  12. 10.1161/circ.77.2.2827913 · DOI
  13. 10.1161/circ.94.12.3115 · DOI
  14. 10.1016/S0002-9149(96)00155-5 · DOI
  15. 10.1161/hyp.27.5.1031 · DOI
  16. Hartmann A Puetz A Hopf R. Effect of long term ACE-inhibitor therapy in hypertrophic cardiomyopathy (HCM). J Am Coll Cardiol. 1995;(suppl A):234A. · DOI
  17. Wigle DE, Marquis Y, Auger P. Pharmacodynamics of mitral insufficiency in muscular subaortic stenosis. Can Med Assoc J. 1967;97:299–301.
  18. Petropoulakis PN, Kyriakidis MK, Tentolouris CA, Kourouklis CV, Toutouzas PK. Changes in phasic coronary blood flow velocity profile in relation to changes in hemodynamic parameters during stress in patients with aortic valve stenosis. Circulation. 1995;92:1434–1437.
  19. 10.1097/00004424-196904020-00005 · DOI
  20. 10.1161/circ.72.1.3159506 · DOI
  21. 10.1016/S0735-1097(86)80305-9 · DOI
  22. 10.1016/0735-1097(94)90631-9 · DOI
  23. Grossman W. Blood flow measurement: the cardiac output. In: Baim DS Grossman W eds. Cardiac Catheterization Angiography and Intervention. Philadelphia Pa: Williams & Wilkins; 1996:109–124.
  24. 10.1161/01.RES.48.6.813 · DOI
  25. Bradley AJ, Alpert JS. Coronary flow reserve. Am Heart J. 1991;122:1117–1128.
  26. Johnston CI. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair and remodeling. Hypertension. 1996;23:258–268.
  27. 10.1007/BF02911386 · DOI
  28. 10.1161/res.62.3.2449296 · DOI
  29. Nosek TM Williams MF Aeigler ST Godt RE. Inositol triphosphate enhances calcium release in skinned cardiac and skeletal muscle. Am J Physiol. 1986;250(Cell Physiol 19):C807–C811. · DOI
  30. 10.1161/circ.87.4.8384939 · DOI
  31. Kyriakidis MK Dernellis JM Androulakis AE Kelepeshis GJ Anastasakis AN Trikas AG Tentolouris C Gialafos JE Toutouzas PK. Changes in phasic coronary blood flow velocity profile and relative coronary flow reserve in patients with hypertrophic obstructive cardiomyopathy. Circulation. In press.
  32. 10.1093/ajh/2.4.294 · DOI
  33. Baker KM, Chernin MI, Wixson SK, Aceto JF. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol. 1990;259:H324–H332.
  34. Linz W, Scholkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens. 1989;2:1325–1350.
  35. 10.1161/circ.87.3.8443912 · DOI
  36. 10.1161/circ.91.1.16 · DOI
  37. Ruddy MC Kostis JB Frishman WH. Drugs that affect the renin-angiotensin system. In: Frishman WH Sonnenblick EH eds. Cardiovascular Pharmacotherapeutics. New York NY: McGraw-Hill Health Professions Division; 1997:131–192.
  38. 10.1056/NEJM199209033271002 · DOI

Cited by

Sorted by citations

Metadata

Authors
Kyriakidis, M., Triposkiadis, F., Dernellis, J., Androulakis, A. E., Mellas, P., Kelepeshis, G. A., & Gialafos, J. E.
Affiliations
From the Department of Cardiology, Laiko Hospital of Athens (M.K., F.T., P.M., G.A.K.); Department of Cardiology, Hippokration Hospital (J.D., A.E.A.), University of Athens; and State Cardiac Department, Hippokration Hospital (J.E.G.), Athens, Greece.
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
1998-04-14
Volume
97
Issue
14
Pages
1342-1347
ISSN
  • 0009-7322
  • 1524-4539
DOI
10.1161/01.cir.97.14.1342
Cited by
42
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review